{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-134476","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.646837+00:00","generated_at":"2026-05-15T08:06:33.255092+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"SCYNEXIS discusses asset acquisition in corporate update call","bullets":["Conference call held on March 31, 2026 covering an asset acquisition transaction.","Slide presentation filed as Exhibit 99.1; no financial terms disclosed in this 8-K.","Company's deck highlights focus on severe rare disease solutions.","No specific revenue, earnings, or closing timeline provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-134476","json":"https://secwatch.observer/filing/0001193125-26-134476.json","markdown":"https://secwatch.observer/filing/0001193125-26-134476.md","text":"https://secwatch.observer/filing/0001193125-26-134476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000119312526134476/0001193125-26-134476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000119312526134476/d114312d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:06:33.255092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}